Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.
https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine
It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.
https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Epstein-Barr Virus Vaccine, Phase I
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1731 Views
-
Last post by Tif
-
- 1 Replies
- 367 Views
-
Last post by Leonard
-
- 1 Replies
- 26 Views
-
Last post by vesta
-
- 2 Replies
- 992 Views
-
Last post by DIM
-
- 0 Replies
- 1370 Views
-
Last post by Tif
-
- 0 Replies
- 1966 Views
-
Last post by Tif
-
- 0 Replies
- 1489 Views
-
Last post by Tif
-
- 1 Replies
- 1125 Views
-
Last post by 1eye
-
- 4 Replies
- 2464 Views
-
Last post by NHE